Story thread · 6 reports / 5 sources

ProMIS jumps after early-stage trial data for Alzheimer’s therapy

seekingalpha.com · 14d

How the coverage leans

Across 5 sources · syndicated copies counted once

First report: ProMIS to host webinar on Alzheimer’s trial interim data — investing.com, 15d

The coverage

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
financialpost.com · 14d
STAT+: Preliminary trial results suggest a path to a safer Alzheimer’s treatment
statnews.com · 14d

The conversation · 0

Sign in to join the conversation.

No comments yet — start the thread.